Keyphrases
Wilms Tumor
81%
Organoids
70%
Tumor
66%
Tumor Organoids
50%
Rhabdomyosarcoma
45%
Organoid Models
33%
Pediatric Tumors
27%
Rhabdoid Tumor
23%
Vulnerability
23%
Renal Tumor
21%
Organoid Culture
20%
Pediatric
20%
Patient Journey
18%
Differentiation State
17%
Patient-derived Organoids
17%
Patient-specific
16%
Pediatric Cancer
16%
Kidney Cancer
15%
Intermediate Risk
15%
RNA Sequencing (RNA-seq)
15%
In Cancer
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Single-cell Transcriptomics
14%
Liquid Biopsy
13%
Tissue Organoids
13%
Neuroblastoma
13%
Tumor-specific
13%
Relapsed or Refractory
13%
Pediatric Radiology
12%
Drug Sensitivity
12%
Older Adults
12%
Tumors in children
11%
Whole Genome Sequencing
11%
Transcription Factor
11%
Patient-derived
10%
Colorectal Cancer
10%
Epigenetic Modification
10%
Cancer Research
10%
Human Colon
10%
Cell Identity
10%
DNA Adduct Formation
10%
Immune Cells
10%
Prognostic Factors
10%
Targeted Therapy
10%
Cell State
10%
Tumor Progression
10%
Nephrogenic Rest
10%
Netherlands
9%
Overall Survival
9%
Molecular Characterization
9%
Metabolic Vulnerability
9%
Paneth Cells
9%
Cell Formation
9%
Narrative Review
9%
Human Intestinal Organoids
9%
Interleukin-22 (IL-22)
9%
Atypical Teratoid
9%
Colorectal Cancer Cells
9%
Somatic Genetics
9%
Acute Lymphoblastic Leukemia
9%
Oncogenic Signaling
9%
Response Evaluation Criteria in Solid Tumors (RECIST)
9%
CRISPR-Cas9 Library
9%
Complex Structural Variation
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Library Screening
9%
Highly Pathogenic
9%
Genetic Changes
9%
CD70
9%
European Guidelines
9%
Natural Killer
9%
Primary Tumor Size
9%
Targeted Locus Amplification
9%
Cancer Differentiation
9%
Human Development
9%
Translocation Renal Cell Carcinoma
9%
Enteroendocrine Cells
9%
Fusion-driven
9%
KMT2A
9%
Cellular Signaling
9%
Repressor
9%
ErbB2
9%
Aristolochic Acid
9%
Effective Model
9%
Aflatoxin B1 (AFB1)
9%
PhIP
9%
Dietary Carcinogen
9%
Translocation RCC
9%
Individual Cells
9%
Knock
9%
T Cells
9%
Somatic Genome
9%
Cancer Plasticity
9%
Immune Suppression
9%
Gene Fusion
9%
Rhabdoid
9%
Alveolar Rhabdomyosarcoma
9%
Healthy Life
9%
Full Life
9%
Virtual Clinical Trials
9%
Medicine and Dentistry
Organoid
100%
Neoplasm
84%
Wilms' Tumor
66%
Pediatrics
54%
Rhabdomyosarcoma
51%
Kidney Tumour
30%
Malignant Neoplasm
29%
Pediatric Cancer
23%
In Vitro
23%
Solid Malignant Neoplasm
21%
Tumor
19%
Liquid Biopsy
18%
RNA Sequence
16%
Malignant Rhabdoid Tumour
16%
Cell Differentiation
16%
Childhood Cancer
15%
Cancer Research
14%
Somatics
14%
Specific Tumor
14%
Transcriptomics
13%
Immunotherapy
13%
Colorectal Carcinoma
13%
Paediatric Radiology
12%
Drug Screening
12%
Overall Survival
12%
Immunocompetent Cell
11%
Disease
11%
Cancer Cell
11%
Drug Sensitivity
11%
Kidney Cancer
10%
Whole Genome Sequencing
10%
Ganglioneuroblastoma
10%
Prognostic Factor
9%
Tumor Progression
9%
Cancer Staging
9%
Systematic Review
9%
Atypical Teratoid Rhabdoid Tumor
9%
Chimeric Antigen Receptor
9%
Primary Tumor
9%
Gene Fusion
9%
Hepatoblastoma
9%
Immunosuppressive Treatment
9%
Morphology
8%
Soft Tissue Sarcoma
8%
Xenograft
8%
Oncology
8%
Carcinogenesis
7%
Cancer Growth
7%
Transcriptome
7%
Adolescence
7%
Clear Cell Renal Cell Carcinoma
7%
Clustered Regularly Interspaced Short Palindromic Repeat
7%
Stem Cell
7%
Nephron
6%
Messenger RNA
6%
Cell-Free DNA
6%
Clinical Trial
6%
Mesoblastic Nephroma
6%
Event Free Survival
6%
Prevalence
6%
Diagnosis
6%
Risk Stratification
6%
Cancer
6%
Transcription Factors
6%
Somatic Mutation
6%
Signal Transduction
6%
Tumor Microenvironment
5%
Vincristine
5%
Dactinomycin
5%
Precursor
5%
Fusion Gene
5%
Translational Research
5%
Biological Marker
5%
Personalized Medicine
5%
Immunity
5%
Colon
5%
Precision Oncology
5%
Biochemistry, Genetics and Molecular Biology
Wilms' Tumor
60%
Epigenetics
30%
RNA Sequence
25%
Genetics
24%
Cellular Differentiation
22%
Carcinogenesis
19%
Genomics
17%
Cancer Cell
16%
Stem Cell
16%
Whole Genome Sequencing
16%
T Cell
16%
Colon
16%
Drug Screening
15%
Transcription Factors
11%
SMARCB1
11%
Messenger RNA
10%
Cancer Stem Cell
10%
CRISPR/Cas9
9%
Gene Expression Profiling
9%
Prevalence
9%
Interleukin 22
9%
CD70
9%
Enteroendocrine Cell
9%
TFE3
9%
KMT2A
9%
Repressor
9%
CRISPR
9%
Gene Fusion
9%
Drug Sensitivity
9%
Chimeric Antigen Receptor
8%
Transcriptomics
8%
Transcriptome
8%
Signal Transduction
7%
Tumor Progression
7%
Germline
7%
Germ Cell
7%
Gene Expression
6%
Wild Type
6%
Cell Proliferation
6%
Morphology
6%
Methylation
6%
Mesenchymal-Epithelial Transition
5%
Oncogene
5%
Exome Sequencing
5%
Somatic Mutation
5%
Precursor
5%
Immunity
5%
Chromatin Remodeling
5%
Targeted Therapy
5%
Phenotypic Heterogeneity
5%